- The World Health Organization (WHO) announced that “the cannabis compound CBD (Cannabidiol) should not be internationally scheduled as a controlled substance” (www.WHO.int)
- WHO has issued preliminary findings indicating that cannabidiol (CBD) shows “no indications of abuse or dependence potential” and “a good safety profile”
- MCOA is committed to the development of high quality CBD-based products
The World Health Organization (“WHO”) officially recommended on December 14, 2017, that the chemical compound cannabidiol (CBD) no longer be internationally scheduled as a controlled substance. WHO has issued a preliminary report that found CBD to be non-addictive and generally safe. The CBD pre-review report (http://nnw.fm/aYG6D), as issued by the agency, states, “In humans, CBD exhibits no effects indicative of any abuse or dependence potential.” The report further indicates that, “CBD is generally well tolerated and with a good safety profile. Reported adverse effects may be as a result of drug-drug interactions between CBD and patients’ existing medications.”
The wholly-owned subsidiary of Marijuana Company of America Inc. (OTC: MCOA), hempSMART™, Inc. is an affiliate marketing company that develops and brings to market hemp-derived cannabinoid-based formulations that are combined with other natural botanicals to create high quality wellness products. HempSMART’s products are now available on the company’s website, www.hempSMART.com. They include hempSMART™ Brain (http://nnw.fm/y5WGz), created as a nootropic product; hempSMART™ Full Spectrum Drops (http://nnw.fm/h5KqL), with more bioavailability; and the newly-released hempSMART™ Pain Capsules (http://nnw.fm/h5KqL).
In a news release, Paula Vetter, a member of hempSMART’s product development team, stated, “HempSMART demonstrated its commitment to formulating a safe and synergistic natural personal care product. The hempSMART Pain formula harnesses the natural power of premium CBD, CBG and active terpenes derived from industrial hemp, combined with complimentary botanicals. Our team is focused on the development of premium personal care products for our customers.”
About hempSMART™ Pain
hempSMART™ Pain Capsules are formulated with 10mg of full dpectrum, non-psychoactive cannabidiol (CBD) per serving, derived from industrial hemp as the core ingredient, which, along with a proprietary blend of other natural ingredients, delivers an all-natural formulation for the temporary relief of minor pain associated with physical activity.
Disclaimer:
- These statements have not been evaluated by the Food and Drug Administration
- This product is not intended to treat, cure, or prevent any disease
For more information, visit the company’s websites at www.MarijuanaCompanyofAmerica.com and
www.hempSMART.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
